[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$praxs
$PRAX sees significant positive analyst ratings and price target increases, with Guggenheim and Piper Sandler reiterating Buy ratings and raising targets. This follows promising data from two epilepsy programs, potentially setting the stage for multiple approvals in 2026.
About $praxs
$praxs is a cryptocurrency project.
Insights
- $praxs sentiment is up XXXXX% from the previous week.
- $praxs creators is up XXX% from the previous X months.
- $praxs engagements is up 3348.22% from the previous X months.
- $praxs mentions is up 1200% from the previous X months.
- $praxs Sentiment hit a 52-Week high of XXX for the day
- $praxs Sentiment hit an all time of XXX for the day
- $praxs Creators hit a 52-Week high of X for the day
- $praxs Creators hit an all time of X for the day
- $praxs Engagements hit a 52-Week high of XXXXX for the day
- $praxs Engagements hit an all time of XXXXX for the day
- $praxs Mentions hit a 52-Week high of XX for the day
- $praxs Mentions hit an all time of XX for the day
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXXXXX +1,193%
X Month: XXXXXX +717%
1-Year High: XXXXX on 2025-12-05
1-Year Low: X on 2025-11-04
Engagements by network (24h): X: XXX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: XX +45%
X Month: XX +229%
1-Year High: XX on 2025-12-05
1-Year Low: X on 2025-07-31
Mentions by network (24h): X: XX
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $praxs in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: X +167%
X Month: X +29%
1-Year High: X on 2025-12-08
1-Year Low: X on 2025-07-31
The most influential creators that mention $praxs in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | X | XXXXX | X | XXX |
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Week: XX% +17%
1-Year High: XXX% on 2025-12-10
1-Year Low: XX% on 2025-12-03
Most Supportive Themes:
- Engagements: (50%) The number of interactions on social media posts related to $praxs.
- Mentions: (50%) The total number of posts mentioning $praxs across social networks.
Most Critical Themes:
Top $praxs Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Guggenheim $PRAX's PT to $XXX from $XXX and reiterated a Buy rating and a 2025 Top Pick. Truist said: Praxis presented compelling new data from two epilepsy programs at the 2025 American Epilepsy Society meeting this past weekend in Atlanta. For relutrigine in SCN2A/8A-DEE the second (and pivotal) cohort of the EMBOLD study (n=51) demonstrated a robust XX% placebo-adjusted (p0.0002) reduction in seizure frequency alongside significant improvements in behavior alertness and communication signals supportive of a disease-modifying effect even over the study's short 16-week duration. The company"
X Link @Quantumup1 2025-12-08T12:13Z 3921 followers, 3522 engagements
"1) We've published an update on Praxis Precision Medicines $PRAX now available at our website. The Company recently hosted a call with HCW in defense of its Essential3 data but $PRAX's defenses only bolstered our concerns"
X Link @CulperResearch 2025-12-02T15:51Z 33.6K followers, 14.6K engagements